ReviewExpert opinion on investigational drugs
SGLT2 inhibitors: an evidence-based update on cardiovascular implications.
Review in Expert opinion on investigational drugs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Effect of sodium glucose cotransporter 2 inhibitors on all cause death and rehospitalization for heart failure in patients with acute myocardial infarction.Scientific reports · 2024Pooled it
- Beyond glucose lowering and ketogenesis: unveiling new cardioprotective mechanisms of SGLT2 inhibitors.Nature reviews. Cardiology · 2026Article
- Review
- Comparative neuroprotective effects of antidiabetic medications on Parkinson's disease risk: a Bayesian network meta-analysis.Journal of global health · 2026Article
- Molecular Mechanisms and Clinical Applications of SGLT2 Inhibitors in Cardiovascular Diseases.Journal of cardiovascular translational research · 2026Review
- Sodium/glucose cotransporters 2 inhibitors but not other antidiabetic drugs improve frailty in older adults with diabetes and heart failure with preserved ejection fraction.Cardiovascular research · 2026Article
- Cardiovascular-kidney-metabolic syndrome: a comprehensive review of pathophysiology, epidemiology, diagnosis, and management.Cardiovascular diabetology · 2026Review
- Metabolic and neuropathic outcomes following combined sodium-glucose cotransporter-2 inhibitor therapy and adjunctive acupuncture in obese patients with diabetic neuropathy: a case series.Frontiers in pain research (Lausanne, Switzerland) · 2026Article
- Astragaloside IV ameliorates cardiomyocyte injury and heart failure through hif/rho/rock pathway regulation: In vitro and in vivo insights.Journal of bioenergetics and biomembranes · 2025Article
- Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2025Review
- SGLT2 inhibitors across the acute cardiac care spectrum: insights and perspectives.Future cardiology · 2025Review
- Article
- GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools?Future cardiology · 2025Article
- Solute carrier protein family: physiological functions, disease associations, and therapeutic potential in immune-related disorders.Frontiers in immunology · 2025Review
- Exogenous Ketones in Cardiovascular Disease and Diabetes: From Bench to Bedside.Journal of clinical medicine · 2024Review
- SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells.Cellular & molecular biology letters · 2024Article
- A Narrative Review of Diabetic Macroangiopathy: From Molecular Mechanism to Therapeutic Approaches.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- Comparative effects of canagliflozin and sitagliptin in chronically ischemic myocardium.Vessel plus · 2024Article
- Association between glycosylated hemoglobin levels, diabetes duration, and left ventricular diastolic dysfunction in patients with type 2 diabetes and preserved ejection fraction: a cross-sectional study.Frontiers in endocrinology · 2023Article
- Editorial: Frailty and oxidative stress.Frontiers in aging · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
introductionSodium Glucose co-Transporter 2 (SGLT2) inhibitors (also known as 'gliflozins') represent a cornerstone to treat diabetes mellitus. Moreover, recent randomized clinical trials have demonstrated important cardioprotective effects of gliflozins, independent of the presence of diabetes. Herein, we summarize the recent therapeutic progress in the cardiovascular field obtained with SGLT2 inhibitors. AREA COVERED: We critically examine the rationale and results of recent clinical studies examining the effects of SGLT2 inhibitors on cardiovascular outcomes, along with a brief overview of the main ongoing trials that have been designed in order to answer the many pending questions in the field of gliflozins and cardiovascular disease. EXPERT OPINION: The favorable results of several clinical trials have broadened the therapeutic scenario for SGLT2 inhibitors, opening, at the same time, new challenges. Additionally, recent preclinical findings have evidenced off-target effects of SGLT2 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.